Form D · Biotechnology
Parabolica Therapeutics, Inc.
Dallas, TX · CIK 0002128979
Offering snapshot reported Apr 30, 2026 · SEC filing
- Reported sold
- $50K Offering amount: $250K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 30, 2026 | Initial | $50,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-582381
Simple Agreement for Future Equity
Source: Form D, filed Apr 30, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian J. Brille | Director |
| Narendra Chokshi | Director, Executive |
| Andrew Wang | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6738 Northport Dr
Dallas, TX, 75230
Dallas, TX, 75230